18F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts

Molecular Imaging and Biology

Volumn 14, Issue 2, 2012, Pages 237-244

  Shah, Nemil ^a   Zhai, Guihua ^b   Knowles, Joseph A ^d   Stockard, Cecil R ^e   Grizzle, William E ^e,f   Fineberg, Naomi ^f   Zhou, Tong ^a   Zinn, Kurt R ^a,b,f   Rosenthal, Eben L ^d   Kim, Hyunki ^b,c,f  

^a and Clinical Center   (United States)

^b University of Alabama   (United States)

^c 803 Shelby Interdisciplinary Biomedical Research Building   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CT; EMMPRIN; FDG PET; Gemcitabine; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER ANTIBODY; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL DENSITY; CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; IN VITRO STUDY; ISOTOPE LABELING; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD147; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CONTRAST MEDIA; DEOXYCYTIDINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84861479808     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0491-5     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Klapman J, Malafa MP (2008) Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15:280-287
3. Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
4. Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11:612-623 (Pubitemid 43967616)
5. Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163-172
6. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275 (Pubitemid 34831525)
7. Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952 (Pubitemid 46630743)
8. Rocha Lima CM, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783 (Pubitemid 41095218)
9. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
10. Abou-Alfa GK, Letourneau R, Harker G et al (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447 (Pubitemid 46630982)
11. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
12. Kindler HL (2007) Pancreatic cancer: an update. Curr Oncol Rep 9:170-176
13. Kindler HL (2005) Front-line therapy of advanced pancreatic cancer. Semin Oncol 32:S33-S36
14. Biswas C, ZhangY, DeCastro R et al (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434-439
15. Suzuki S, Sato M, Senoo H, Ishikawa K (2004) Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 293:259-266 (Pubitemid 38083215)
16. Ellenrieder V, Alber B, Lacher U et al (2000) Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 85:14-20
17. Tang Y, Nakada MT, Kesavan P et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193-3199 (Pubitemid 40524601)
18. Bougatef F, Quemener C, Kellouche S et al (2009) EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 114:5547-5556
19. Zheng HC, Takahashi H, Murai Y et al (2006) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95:1371-1378 (Pubitemid 44760088)
20. Riethdorf S, Reimers N, Assmann V et al (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119:1800-1810 (Pubitemid 44356836)
21. Dandekar M, Tseng JR, Gambhir SS (2007) Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 48:602-607 (Pubitemid 47571417)
22. Kroep JR, Van Groeningen CJ, Cuesta MA et al (2003) Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 5:337-346 (Pubitemid 38100894)
23. Kelloff GJ, Hoffman JM, Johnson B et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808 (Pubitemid 40525178)
24. Barber TW, Kalff V, Cherk MH, Yap KS, Evans P, Kelly MJ (2010) (18)F-FDG PET/CT influences management in patients with known or suspected pancreatic cancer. Intern Med J. doi:10.1111/j.1445-5994.2010.02257.x
25. Mataki Y, Shinchi H, Kurahara H et al (2009) Clinical usefulness of FDG-PET for pancreatic cancer. Gan To Kagaku Ryoho 36:2516-2520
26. Maisey NR, Webb A, Flux GD et al (2000) FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 83:287-293 (Pubitemid 30453565)
27. Higashi T, Sakahara H, Torizuka T et al (1999) Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 40:1424-1433 (Pubitemid 29428922)
28. Kuwatani M, Kawakami H, Eto K et al (2009) Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 48:867-875
29. Schellenberg D, Quon A, Minn AY et al (2010) 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77:1420-1425
30. Schneiderhan W, Diaz F, Fundel M et al (2007) Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci 120:512-519 (Pubitemid 46332514)
31. Larsen SK, Solomon HF, CaldwellG,AbramsMJ (1995) [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem 6:635-638
32. Lowry O, Rosebrough N, Farr L, Randall R (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
33. Prasad R, Ratib O, Zaidi H (2010) Performance evaluation of the FLEX triumph X-PET scanner using the national electrical manufacturers association NU-4 standards. J Nucl Med 51:1608-1615
34. Kim H, Morgan DE, Buchsbaum DJ et al (2008) Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 68:8369-8376
35. Hertzog C, Rovine M (1985) Repeated-measures analysis of variance in developmental research: selected issues. Child Dev 56:787-809
36. Rodgers JL, Nicewander WA (1988) Thirteen ways to look at the correlation coefficient. Am Stat 42:59-66
37. Escorcia FE, Henke E, McDevitt MR et al (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70:9277-9286
38. Dean NR, Newman JR, Helman EE et al (2009) Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15:4058-4065